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 ABSTRACT
A 50-year-old post-menopausal recipient of a kidney allograft with bone pain, osteoporosis, persistent 
hypercalcaemia and elevated parathormone (PTH) levels, despite a satisfactory graft function, was treated 
with bisphosphonates and cinacalcet starting, respectively, 5 and 6 months after renal transplantation (RT). 
Sixteen months after treatment, there was improvement of bone mineral density (BMD) measured by dual-
energy X-ray absorptiometry (DEXA).  A bone biopsy was taken, unveiling a surprising and worrisome result. 
Post-RT bone disease is different from classic CKD-MBD and should be managed distinctly, including, in 
some difficult cases, an invasive evaluation through the performance of a bone biopsy, as suggested in the 
KDIGO guidelines.
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 RESUMO
Uma transplantada renal de 50 anos, pós menopáusica, com dor óssea, osteoporose, hipercalcémia 
persistente e níveis elevados de paratormona, apesar de uma razoável função do enxerto renal, foi tratada 
com bifosfonatos e cinacalcet com início 5 e 6 meses, respectivamente, após a transplantação renal. Verificou-
se melhoria da densidade óssea medida por DEXA. Foi realizada uma biópsia óssea que revelou um resultado 
inesperado e preocupante. A doença óssea após a transplantação renal é diferente da DMO-DRC clássica 
e deve ser gerida de forma distinta. Nalguns casos, como o ilustrado na presente apresentação, justifica-se 
o diagnóstico invasivo através do recurso à realização de uma biópsia óssea, como é proposto nas orien-
tações da KDIGO.
Palavras-Chave: Biópsia óssea; cinacalcet; dmo-drc; hipercalcemia; osteoporose; transplantação renal.
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 INTRODUCTION
The most frequent post-renal transplantation (RT) 
bone disease is characterized by accelerated loss of 
bone mineral density and increased risk of fractures. 
There are no randomized clinical trials in kidney trans-
plant patients examining bone specific therapies on 
clinical outcomes, such as fractures or cardiovascular 
disease events. Bone disease in kidney transplant 
patients is heterogeneous, involving pre-existing renal 
osteodystrophy, the effects of immunosuppression 
therapy on bone and the effects of reduced renal 
function after RT; these factors overlap and result in 
different pathologic states. Several pharmacologic 
therapies that target multiple components of the MBD 
imbalance have been used.
Kidney Disease: Improving Global Outcomes (KDI-
GO) clinical practical guidelines for the care of kidney 
transplant recipients includes the management of 
transplant bone disease. The KDIGO latest guidelines 
on CKD-MBD were issued in 2009; a conference on 
controversies on this very issue was announced to 
be held in October 2013. Its purpose was to evaluate 
what is known about CKD-MBD, what can be done 
with what is known and what needs to be learned1. 
This case report of hypercalcaemic hyperparathy-
roidism after RT discloses that urgent need.
 CASE REPORT
A 50-year-old white woman was submitted to RT in 
October 2009. Her immunosuppression consisted of 
basiliximab (first and fourth RT days), methylpredniso-
lone (500-250-125-80 mg in RT days 1-4, respectively), 
prednisone (35 mg at RT day 5, followed by progressive 
tapering until 5 mg at RT day 30), tacrolimus and 
mycophenolate mofetil. She had autosomal dominant 
polycystic kidney disease and had been on haemodi-
alysis since January 2005. Prior to RT there was a long 
history of symptomatic herniated vertebral disc; she 
was referred to Neurosurgery, but only functional reha-
bilitation was recommended. She had no other relevant 
comorbidity. Age of menarche was 13 years, with spon-
taneous menopause at age 47. She was slightly over-
weight (body mass index 27) and a non-smoker.
While on haemodialysis, the patient´s mineral 
serum values were remarkable for hyperphosphatemia, 
with phosphorus ranging 4.1-7.1 mg/dl, calcium 8.0-
9.9 mg/dl, calcium-phosphorus product 35-61 (mg/
dl)2 and intact parathormone (iPTH) between 108-170 
pg/ml . She was on sevelamer 800 mg, 6 to 9 pills 
qd and calcium carbonate 1000 mg 3 to 6 pills qd 
for over three years; no vitamin D or calcimimetic 
were taken.
Five months after RT her gynaecologist found she 
had reduced BMD: a dual-energy x-ray absorptiometry 
(DEXA) revealed lumbar spine osteoporosis (T-score 
-2.5 SD) and femoral neck osteopenia (T-score -2.1 
SD). He prescribed alendronic acid 70 mg every week.
Six months after RT, the patient maintained rea-
sonable kidney graft function, with a serum creatinine 
of 1.1 mg/dl (estimated glomerular filtration rate by 
CKD-EPI Creatinine Equation of 59 ml/min/1.73m2). 
She had persistent moderate hyperparathyroidism 
(iPTH 220 pg/ml) and hypercalcaemia (maximum 11.4 
mg/dl). Cinacalcet was then initiated, 30 mg po qd. 
Plasma calcium levels slightly decreased, without a 
significant PTH levels change (190-210 pg/ml) (Graph-
ics I and II).
Eight months after RT she suffered a traumatic 
hip fracture.
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Graphics I and II
Laboratory serum values of calcium and phosphorus (Table I) and iPTH 
(Table II) at the time of RT, 6, 12 and 24 months after RT.
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Twenty-two months after RT a new DEXA-scan showed 
a significant increase of femoral neck bone density 
(T-score -1.5 SD), compared with the previous exam; 
lumbar spine density was similar (T-score -2.6 SD).
During all RT period, the patient continued to 
suffer widespread bone pain, mostly lumbar pain, 
which she recognized as a consequence of the degen-
erative bone disease identified well before RT. This 
clinical condition interfered markedly with her well-
being, not only because of the psychological distress 
associated with constant pain, but also by the pro-
gressively compromised physical activity. Besides 
that, this period had been unremarkable, despite a 
fall that resulted in the bone fracture previously 
referred and some minor urinary tract infections. 
Two years after RT (at the 23rd month), a bone 
biopsy was performed (Fig. 1). Serum PTH was still 
elevated at 191 pg/ml; calcium, phosphorus and alka-
line phosphatase were within normal values; 
25-hydroxy vitamin D level was 41.3 nmol/L (normal 
values 75-250 nmol/L); thyroid blood tests were nor-
mal. The biopsy revealed severe osteoporosis and 
adynamic bone disease (“Frozen Bone”), with normal 
bone mineralization. The patient maintained satisfac-
tory graft function (serum creatinine 0.9-1.2 mg/dl).
Alendronate and cinacalcet were immediately dis-
continued and cholecalciferol (1.334 IU of vitamin 
D3 per day) was added. A few weeks later, the 
patient felt quite better, with bone pain remission 
and physical activity resumed. Weight-bearing physi-
cal activity was encouraged, and she started gym-
nastic classes with great physical improvement. Her 
most recent relevant serum laboratory values, 10 
months after the bone biopsy, are creatinine 1.19 
mg/dl, calcium 11.1 mg/dl, phosphorus 2.5 mg/dl, 
PTH 139.5 pg/ml. She has a vascular calcification 
Adragão score of 0 /8 (no vascular calcification 
observed on pelvis and hand plain x-ray) and a 
Kauppila score of 2 /24 (vascular calcification on 
abdominal aorta seen on lateral abdomen plain 
x-ray.)
 DISCUSSION
We report a case of CKD-MBD in a post-menopau-
sal kidney transplant recipient (after almost 5 years 
on haemodialysis), who had lumbar spine osteopo-
rosis and femoral osteopenia with eGFR around 60 
mL/min/1.73m2, treated with bisphosphonates to 
whom, in face of persistent hypercalcaemia and 
hyperparathyroidism, cinacalcet was added. Skeletal 
history was significant for pre-RT symptomatic herni-
ated vertebral disc and progressive disabling bone 
pain thereafter. Hypercalcaemia came to normal val-
ues and PTH remained high. Meanwhile, a (traumatic) 
Figure 1
Transiliac crest bone biopsy with doxycycline labeling and histomorphometric analysis:  absent active osteoblasts; intense reduction of cortical bone 
and trabecular volume: severe osteoporosis in the context of adynamic disease.
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bone fracture occurred. She maintained reasonable 
good graft function and bone density (by DEXA scan) 
was ameliorated, but her symptoms did not improve. 
A bone biopsy was diagnostic for adynamic bone 
disease.
This case illustrates the mandatory use of bone 
histomorphology to manage BMD in RT patients. The 
risks associated with bisphosphonates and calcimi-
metics on RT, despite good graft function, are enlight-
ened here; although prescribed according to prevail-
ing recommendations, their use resulted in unwanted 
clinical consequences. 
 Low bone mineral density
Post-RT bone disease comprises a spectrum of 
metabolic alterations of bone remodelling that include 
pre-existing renal osteodystrophy alterations, as well 
as new factors that occur after transplantation, being 
influenced by immunosuppressive therapy, kidney 
transplant function, hypophosphatemia, and distur-
bances in the fibroblastic growth factor 23-PTH-vita-
min D axis2,3. Many studies in transplant recipients 
have shown a negative correlation between gluco-
corticoid cumulative dose and BMD. The mechanisms 
whereby glucocorticoids may affect bone metabolism 
are multifactorial; these drugs increase osteoclastic 
resorption, decrease osteoblastic activity and promote 
osteoblast apoptosis; they also may indirectly affect 
bone metabolism by decreasing intestinal calcium 
absorption and increasing renal calcium wasting, lead-
ing to increased PTH secretion. Secondary hypog-
onadism further reduces bone formation3,4. The role 
of calcineurin inhibitors regarding rates of bone mass 
loss is less clear and limited information is available 
on mycophenolate mofetil or basiliximab. Our patient 
did not have a high cumulative glucocorticoid dose, 
although she was not on a corticoid-sparing regimen; 
she also had the physiologic decrease in gonadal 
steroids that is associated with menopause. Pre-RT 
osteodystrophy (with iPTH in the low/normal range), 
highly daily calcium carbonate over that period (3 to 
6 grams), corticosteroid use, hypogonadal state, bis-
phosphonate and cinacalcet therapy likely contributed 
to her adynamic bone disease.
Accelerated loss of bone density occurs in the 
first year after RT, mainly in the first 3 to 6 months; 
after the first year, studies are conflicting5-9. The use 
of bisphosphonates post-transplantation has been 
shown to prevent loss or increase BMD10-15. However, 
there has generally been no evidence of fracture 
reduction16, and bisphosphonate treatment carries 
the risk of inducing or prolonging adynamic bone 
disease in the presence of renal dysfunction17. Bis-
phosphonate deposition in the bone mineralization 
can last 10 years, as emphasized in a recent review 
by Susan Ott18. This long deposition and the interfer-
ence with bone remodelling should be taken into 
account before the initiation of this therapy. As these 
drugs are eliminated (almost exclusively) by the kid-
ney, renal function after kidney transplantation has 
also to be considered.
In this patient, the bisphosphonates prescribed 
by the gynaecologist for osteoporosis treatment 
potentially could lower serum calcium concentration, 
but hypercalcaemia persisted. In face of persistent 
hypercalcaemia with elevated PTH, cinacalcet was 
introduced. Several small studies showed that cina-
calcet was able to lower the serum calcium, with no 
significant change in the PTH values19-21.
BMD provides no information regarding bone qual-
ity, bone mineralization, bone architecture or turnover 
in RT population22. Nevertheless, KDIGO suggests to 
measure BMD in the first 3 months after RT when 
patients have GFR > 30 mL/min/1.73m2 (evidence grade 
2D) and, when low, to consider treatment with vitamin 
D, calcitriol/alfacalcidiol or bisphosphonates (evidence 
grade 2C). They also refer that treatment choices may 
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Graphics III
Percentage change in vertebral bone mineral density.
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be inﬂuenced by the presence of CKD–MBD, as indi-
cated by abnormal levels of calcium, phosphorus, 
PTH, alkaline phosphatases and 25(OH)vitamin D. 
KDIGO guidelines also defend that it is reasonable to 
consider the need to perform a bone biopsy to guide 
treatment (Not Graded)23. The Spanish Nephrology 
Society guidelines launched 2 years ago go even 
further on that issue: they recommend a DEXA scan 
to kidney recipients with fracture risk and, if it reveals 
osteoporosis and PTH is > 60 pg/ml, to start bispho-
sphonates; they also recommend calcimimetics after 
RT if serum calcium > 10.5 mg/dl and iPTH > 100 pg/
ml24. Of note, the KDOQI US commentary on KDIGO 
guidelines already stated that bisphosphonates should 
not be used if there are abnormalities in calcium, 
phosphate, vitamin D, or PTH levels25.
 Hypercalcaemia
Hypercalcaemia after kidney transplantation is 
common and often transient in the first 6 months, 
but cannot fade away in some patients. Tubuloint-
erstitial calcifications in the kidney graft have been 
demonstrated in RT patients with high serum PTH 
and calcium levels in a well-known study, which 
correlated with an inferior graft outcome one year 
after transplantation, and hyperparathyroidism and 
hypercalcaemia were identified as the key factors26. 
Of note, phosphate supplementation was more preva-
lent in patients with tubulointerstitial calcifications; 
moreover, in a subsequent study with 3.5 times more 
patients, high calcium levels were associated with a 
reduced risk for allograft loss27. 
Usually hypercalcaemia is due to hyperparathy-
roidism that persists from the previous pre-RT period, 
and results from the direct effect of PTH in causing 
calcium efflux from the bone now added to the 
enhanced renal tubular absorption of calcium by PTH 
action in the functioning kidney graft, and to the 
effects of higher levels of calcitriol on the gastroin-
testinal absorption of calcium by the restoring of 1 
α-hydroxylase activity subsequent to functioning 
nephron mass. 
 Hyperparathyroidism
In up to 50% of transplant recipients, abnormal PTH 
secretion persists, sometimes causing hypercalcaemia 
that may require parathyroidectomy28. Cinacalcet has 
been shown to correct hypercalcaemia and hyperpar-
athyroidism in several trials in kidney transplant recipi-
ents19,20,29-36, however, few of those studies had a 
control group and none had bone biopsies. One of the 
concerns with calcimimetics is nephrocalcinosis and 
graft dysfunction (3 case reports in the literature)37-39. 
In a recent study by Courbebaisse et al., 34 patients 
received cinacalcet between 3 to 12 months after RT; 
hypercalciuria was more than twice as high at month 
12 as in patients who did not receive cinacalcet treat-
ment, but that was not associated with an increase in 
calcium deposits on renal biopsies or an alteration of 
measured GFR30.
Biochemical parameters of bone metabolism, 
although somewhat useful in monitoring bone health 
in the non-renal transplant patient, do not predict 
bone activity or mineralization in the renal transplant 
recipient, suggesting a skeletal resistance to PTH 
and eventually also to active vitamin D340-42. Nev-
ertheless, some experts suggest that management 
of post-transplantation bone disease should initially 
focus on correcting metabolic disorders, using the 
same principles applied to manage CKD–MBD prior 
to RT2, 23,24, and consider bone biopsy as an impor-
tant, yet eventual, additional tool.
The remarkable clinical evolution in this case 
report, causing high morbidity and affecting the qual-
ity of life of this transplant recipient, which greatly 
improved after changing therapeutic strategy, 
acknowledges that an improved BMD may not reflect 
an improvement on bone health. These results also 
underline that adynamic bone histology may coexist 
with high iPTH serum levels in the transplanted 
patients (as already described in the dialysis 
population43,44).
Recognition of MBD in RT patients as a unique 
disorder is critical to provide appropriate therapy 
and avoid iatrogenesis. We believe that the new 
version of KDIGO guidelines will update current guide-
lines on this topic. 
 CONCLUSIONS
Especially after RT, biochemical hyperparathy-
roidism is a complex entity that can be associated 
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with high or low bone turnover.  Treatment of per-
sistent hypercalcaemia according to some prevailing 
recommendations can lead to, or exacerbate, ady-
namic bone disease. Presently, it is not known if 
and at what calcium level treatment should be 
initiated. 
In the absence of any randomized controlled trial 
for the treatment of renal osteodystrophy after RT, it 
seems wise to begin the therapeutic approach by the 
correction of deficiency/insufficiency of vitamins, hor-
mones and minerals as we did in the present situation, 
through the supplementation of cholecalciferol.
Our findings also suggest that before the use of 
a long acting drug (like bisphosphonates) or an off 
label drug (like cinacalcet) in a transplanted patient, 
a bone biopsy should be performed to evaluate bone 
characteristics: volume, mineralization, quality and 
architecture (with separation between cortical and 
trabecular bone).
The presented case draws attention to the fact 
that we must focus on the trigger event, instead of 
its manifestations.
Conflict of interest statement: None declared.
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